GLUTAMATE-RELATED BIOMARKERS IN DRUG DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM PLANNING COMMITTEE*

DANIEL JAVITT (Cochair), New York University

CHI-MING LEE (Cochair), AstraZeneca Pharmaceuticals

HUDA AKIL, University of Michigan

MARK BEAR, Massachusetts Institute of Technology

JOHN DUNLOP, Pfizer

RICHARD FRANK, GE Healthcare, Inc.

WALTER KOROSHETZ, National Institute of Neurological Disorders and Stroke

MENELAS PANGALOS, AstraZeneca Pharmaceuticals

WILLIAM POTTER, Foundation for NIH Neuroscience Biomarker Steering Committee

RAE SILVER, Columbia University

NORA VOLKOW, National Institute on Drug Abuse

STEVIN ZORN, Lundbeck Research

STEPHEN ZUKIN, AstraZeneca Pharmaceuticals

Study Staff

BRUCE M. ALTEVOGT, Project Director, Institute of Medicine

SARAH L. HANSON, Associate Program Officer (until June 2010)

SARA SHNIDER, Christine Mirzayan Science and Technology Policy Graduate Fellow (until May 2010)

LORA K. TAYLOR, Senior Project Assistant, Institute of Medicine

Footnotes

*

Institute of Medicine planning committees are solely responsible for organizing the workshop, identifying topics, and choosing speakers. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.